Please login to the form below

Not currently logged in
Email:
Password:

avelumab

This page shows the latest avelumab news and features for those working in and with pharma, biotech and healthcare.

BMS CEO tackles investor ‘frustrations’ on immuno-oncology

BMS CEO tackles investor ‘frustrations’ on immuno-oncology

inhibitor Bavencio (avelumab) – both given in tandem with Pfizer’s tyrosine kinase inhibitor Inlyta (axitinib) – leading to them being touted as a potential new treatment standard for these patients.

Latest news

More from news
Approximately 11 fully matching, plus 29 partially matching documents found.

Latest Intelligence

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    They include Pfizer’s OX40 agonist PF-04518600, in early-stage testing in combination with the company’s Bavencio (avelumab) and targeted cancer drug Inlyta (axitinib) as well as chemotherapy,

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

  • Merck appoints ex-Pfizer exec as global head of oncology Merck appoints ex-Pfizer exec as global head of oncology

    In this role, she will be responsible for defining the pharmaceutical company's integrated global oncology strategies and delivering therapeutic launches, including the commercial launch of Avelumab, a non-small cell

  • Merck appoints new senior vice president Merck appoints new senior vice president

    His expertise and fresh perspective will add significant value to our early-stage immuno-oncology portfolio including combination and biomarker strategies for avelumab and other clinical candidates, as we endeavour to

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
dna Communications

Healthcare communications with unique thinking, insight and attitude...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Infographics